PriceTargets.com logo

Creative Medical Technology - CELZ Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.07 As of 12/20/2024 06:51 PM ET
▲ +0.07 (3.50%)

This chart shows the closing price for CELZ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Creative Medical Technology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CELZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CELZ

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Creative Medical Technology in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.07.

This chart shows the closing price for CELZ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Creative Medical Technology. This rating has held steady since January 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/25/2022Roth CapitalInitiated CoverageBuy$100.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Creative Medical Technology logo
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Read More

Today's Range

Now: $2.07
Low: $2.00
High: $2.17

50 Day Range

MA: $3.05
Low: $2.00
High: $5.35

52 Week Range

Now: $2.07
Low: $1.96
High: $10.28

Volume

21,219 shs

Average Volume

67,203 shs

Market Capitalization

$3.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Creative Medical Technology?

The following Wall Street analysts have issued stock ratings on Creative Medical Technology in the last year:
View the latest analyst ratings for CELZ.

What is the current price target for Creative Medical Technology?

0 Wall Street analysts have set twelve-month price targets for Creative Medical Technology in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Creative Medical Technology in the next year.
View the latest price targets for CELZ.

What is the current consensus analyst rating for Creative Medical Technology?

Creative Medical Technology currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CELZ.

What other companies compete with Creative Medical Technology?

Other companies that are similar to Creative Medical Technology include Spruce Biosciences, NKGen Biotech, Bright Green, GlycoMimetics and Minerva Neurosciences. Learn More about companies similar to Creative Medical Technology.

How do I contact Creative Medical Technology's investor relations team?

Creative Medical Technology's physical mailing address is 2017 W Peoria Ave, PHOENIX, AZ 85029-4916, United States. The company's listed phone number is (833) 336-7636 and its investor relations email address is [email protected]. The official website for Creative Medical Technology is www.creativemedicaltechnology.com. Learn More about contacing Creative Medical Technology investor relations.